M.D. Anderson Cancer Center Clinical Trials — 77 Active Studies

NCT01746836 Phase 2

Recruiting

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

NCT03128879 Phase 2

Recruiting

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

Chronic Lymphocytic Leukemia

NCT01492036

Recruiting

Long-Term Follow-Up of Recipient of Gene Transfer Research

Retroviridae Infections

NCT03114462 Phase 1

Recruiting

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

Malignant Neoplasms of Respiratory and Intrathoracic Organs

NCT03471260 Phase 1, Phase 2

Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Acute Myeloid Leukemia

NCT05064280 Phase 2

Recruiting

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Brain Metastases

NCT06872723

Recruiting

CPRIT: Patient Adherence to Lung Cancer Screening

Lung Cancer Screening

NCT00539162

Recruiting

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women

Ovarian Cancer

NCT06444880 Phase 2

Recruiting

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

SMARCB1-Deficient Malignancies

NCT06006273 Phase 1

Recruiting

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Refractory Solid Tumors

NCT06083883 Phase 1

Recruiting

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Synovial Sarcoma

NCT07147205

Recruiting

Evaluation of Meaning-centered Group Psychotherapy in Integrative Medicine

Psychotherapy

NCT05554133

Recruiting

Precision Optical Guidance for Oral Biopsy

Oral Lesions

NCT06414902 Phase 1

Recruiting

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

Esophageal Cancer

NCT04629677

Recruiting

Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers

Malignant Digestive System Neoplasm

NCT04947254 Phase 2

Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Prostate Carcinoma

NCT05336383 Phase 2

Recruiting

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Multiple Myeloma

NCT04169737 Phase 2

Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Chronic Lymphocytic Leukemia

NCT05529069 Phase 2

Recruiting

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma

NCT01624805 Phase 2

Recruiting

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Aplastic Anemia

NCT06130254 Phase 1

Recruiting

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Advanced Solid Tumor

NCT04984551 Phase 2

Recruiting

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

Advanced Malignant Solid Neoplasm

NCT06113302 Phase 2

Recruiting

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

NCT07128381 Phase 1, Phase 2

Recruiting

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Myelofibrosis (MF)

NCT05546827 Phase 2

Recruiting

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma

Sinonasal Melanoma

NCT01515527 Phase 2

Recruiting

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Leukemia

NCT05026983 Phase 2

Recruiting

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Clinical Stage IV Cutaneous Melanoma AJCC v8

NCT05054296 Phase 2

Recruiting

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

Biochemically Recurrent Prostate Carcinoma

NCT05342454

Recruiting

A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain

Brain Tumor

NCT05343013 Phase 2

Recruiting

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal Cancer

NCT05967182 Phase 2

Recruiting

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma

NCT05365035 Phase 2

Recruiting

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Myelodysplastic Syndromes

NCT06722846

Recruiting

Communicating Health Options to Inform Care and Empower Strategic Care Planning (CHOICES): A Multi-layer Randomized Case Vignette Study.

Health Options

NCT05053113

Recruiting

Utilization of a Peer-Based Approach for the Promotion of Physical Activity in Inactive Women

Obesity-Related Malignant Neoplasm

NCT07136077 Phase 2

Recruiting

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Minimal Residual Disease

NCT06409052

Recruiting

Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women

Endometrial Cancer

NCT01371630 Phase 1, Phase 2

Recruiting

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

NCT01772771

Recruiting

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

Glioma

NCT05947838

Recruiting

A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma

Appendiceal Adenocarcinoma

NCT07220096

Recruiting

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes

Lung Cancer

NCT04693468 Phase 1

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm

NCT07053059 Phase 2

Recruiting

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

Acute Lymphocytic Leukemia (ALL)

NCT05394259 Phase 1

Recruiting

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

Pancreatic Cancer

NCT06474676 Phase 1

Recruiting

T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.

Metastatic Soft-tissue Sarcoma

NCT06261060 Phase 2

Recruiting

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Familial Platelet Disorder

NCT03911388 Phase 1

Recruiting

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Neoplasms, Brain

NCT06162403

Recruiting

Exploring the Benefit of Peripheral Nerve Stimulation in Treating Pain From Chemo-induced Peripheral Neuropathy: A Longitudinal Single Center Feasibility Study

Peripheral Nerve Stimulation

NCT02863172

Recruiting

Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes

Hereditary Colorectal Cancer Syndrome

NCT02379377 Phase 1

Recruiting

18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

Adult Hepatocellular Carcinoma

NCT07218939

Recruiting

Universal Biospecimen Collection Protocol for Extra Material From Clinical Pulmonary Procedures

Pulmonary

NCT06548412 Phase 1, Phase 2

Recruiting

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Metastatic Biliary Tract Cancer

NCT06259253

Recruiting

Understanding Patient Experience Among Asians at MD Anderson

Cancer

NCT03589729 Phase 2

Recruiting

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid Leukemia

NCT06004336 Phase 2

Recruiting

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Oligometastatic Renal Cell Carcinoma

NCT05053867 Phase 3

Recruiting

A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients

Pulmonary Hemorrhage

NCT06736600

Recruiting

Patient-identified Values as Outcome Targets (PIVOT) Feasibility Pilot Trial

Peripheral Neuropathy Due to Chemotherapy

NCT01365169

Recruiting

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Malignant Head and Neck Neoplasm

NCT07186556

Recruiting

Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention

Cancer

NCT02115295 Phase 2

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Biphenotypic Leukemia

NCT06308419 Phase 1

Recruiting

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Leiomyosarcoma

NCT04913311

Recruiting

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Lung Non-Small Cell Carcinoma

NCT05335811 Phase 1

Recruiting

First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging

Endocrine Neoplasia

NCT05834244 Phase 1

Recruiting

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Acute Myeloid Leukemia

NCT03093909 Phase 1

Recruiting

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

Malignant Neoplasm of Bone and Articular Cartilage

NCT00477100

Recruiting

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

Inflammatory Breast Carcinoma

NCT06108232 Phase 2

Recruiting

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Follicular Lymphoma

NCT06431347

Recruiting

Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health

Transplant and Cell Therapy

NCT06414889 Phase 1

Recruiting

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

RUNX1 Familial Platelet Disorder

NCT06563505 Phase 2

Recruiting

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

Lymphoma

NCT04776941

Recruiting

Expressive Writing for the Management of Stress in Cancer Survivors

Hematopoietic and Lymphoid Cell Neoplasm

NCT06295783

Recruiting

Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect

Radiation

NCT07009886

Recruiting

Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy

Advanced Cancer

NCT05474846 Phase 2, Phase 3

Recruiting

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

Sleep

NCT03425526 Phase 1

Recruiting

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Hematopoietic and Lymphoid Cell Neoplasm

NCT07229417 Phase 2

Recruiting

IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

Metastatic Endocrine Refractory

NCT05101213 Phase 1

Recruiting

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Adenovirus Infection

NCT06959550 Phase 2

Recruiting

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer